Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in caucasian patients with stage I–II hypertension
Sy'chev D. A., Shikh N., Morozova T. E., Grishina E., Ryzhikova K., Malova E.
Pharmacogenomics and Personalized Medicine
Vol.11, P. 157-165
Опубликовано: 2018
Тип ресурса: Статья
Аннотация:
Purpose: The aim of this study was to determine the impact of ABCB1 (MDR1) rs1045642 polymorphisms on the efficacy and safety of amlodipine in Caucasian patients. Patients and methods: The 12-week study included 100 patients. Patients with the newly diagnosed stage I–II hypertension (HT) were recruited to complete genotyping of the rs1045642 single-nucleotide polymorphism (SNP). The study design did not include a control group. Before treatment, all patients either did not undergo antihypertensive treatment at all or did not receive regular antihypertensive therapy. The initial dose was 5 mg/day. Four office blood pressure measurements, two 24-hour noninvasive ambulatory blood pressure measurements, and questionnaires of Tsvetov were used to evaluate the efficacy and safety of amlodipine. Results and conclusion: The highest antihypertensive effect in combination with the lowest incidence of adverse reactions was observed in the TT group, while patients with the CC genotype showed a low
Ключевые слова:
CYP3A5; P-glycoprotein; Personalized; Pharmacodynamics; rs1045642; Side effects; Single-nucleotide polymorphism; SNP
amlodipine; multidrug resistance protein 1; ABCB1 gene; adult; ankle edema; antihypertensive activity; Article; blood pressure measurement; Caucasian; diastolic blood pressure; drug dose increase; drug efficacy; drug safety; drug tolerability; female; genotype; human; hyperemia; hypertension; incidence; leg edema; major clinical study; male; middle aged; non invasive measurement; pharmacogenetics; prescription; questionnaire; recommended drug dose; Russian Federation; single nucleotide polymorphism; skin redness; systolic blood pressure; treatment duration
Язык текста: Английский
ISSN: 1178-7066
Sy'chev D. A. Dmitrij Alekseevich 1975-
Shikh N.
Morozova T. E. Tat`yana Evgenyevna 1958-
Grishina E.
Ryzhikova K.
Malova E.
Сычев Д. А. Дмитрий Алексеевич 1975-
Ших Н.
Морозова Т. Е. Татьяна Евгеньевна 1958-
Гришина Е.
Рyжикова К.
Малова Е.
Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in caucasian patients with stage I–II hypertension
Текст визуальный непосредственный
Pharmacogenomics and Personalized Medicine
Vol.11 P. 157-165
2018
Статья
CYP3A5 P-glycoprotein Personalized Pharmacodynamics rs1045642 Side effects Single-nucleotide polymorphism SNP
amlodipine multidrug resistance protein 1 ABCB1 gene adult ankle edema antihypertensive activity Article blood pressure measurement Caucasian diastolic blood pressure drug dose increase drug efficacy drug safety drug tolerability female genotype human hyperemia hypertension incidence leg edema major clinical study male middle aged non invasive measurement pharmacogenetics prescription questionnaire recommended drug dose Russian Federation single nucleotide polymorphism skin redness systolic blood pressure treatment duration
Purpose: The aim of this study was to determine the impact of ABCB1 (MDR1) rs1045642 polymorphisms on the efficacy and safety of amlodipine in Caucasian patients. Patients and methods: The 12-week study included 100 patients. Patients with the newly diagnosed stage I–II hypertension (HT) were recruited to complete genotyping of the rs1045642 single-nucleotide polymorphism (SNP). The study design did not include a control group. Before treatment, all patients either did not undergo antihypertensive treatment at all or did not receive regular antihypertensive therapy. The initial dose was 5 mg/day. Four office blood pressure measurements, two 24-hour noninvasive ambulatory blood pressure measurements, and questionnaires of Tsvetov were used to evaluate the efficacy and safety of amlodipine. Results and conclusion: The highest antihypertensive effect in combination with the lowest incidence of adverse reactions was observed in the TT group, while patients with the CC genotype showed a low